AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 5-hydroxytryptamine receptor 2B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P41595

UPID:

5HT2B_HUMAN

Alternative names:

Serotonin receptor 2B

Alternative UPACC:

P41595; B2R9D5; Q53TI1; Q62221; Q6P523

Background:

The 5-hydroxytryptamine receptor 2B, also known as the Serotonin receptor 2B, is a pivotal G-protein coupled receptor. It binds to serotonin and various ergot alkaloid derivatives, initiating a cascade of signaling events. This receptor modulates neural activity by regulating dopamine and serotonin release and uptake, impacting behaviors such as impulsivity and pain perception. It also plays critical roles in heart development, osteoblast proliferation, and pulmonary artery adaptation.

Therapeutic significance:

Understanding the role of 5-hydroxytryptamine receptor 2B could open doors to potential therapeutic strategies. Its involvement in neurotransmitter regulation, heart development, and bone density maintenance highlights its potential as a target for treating related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.